Artiva Biotherapeutics (ARTV)
Develops cryopreserved allogeneic NK-cell candidates for autoimmune diseases and cancer.
Something off on this page? Send us feedback.
Develops AlloNK, an off-the-shelf, cryopreserved allogeneic NK-cell therapy candidate for B-cell-driven autoimmune diseases. Its pipeline also includes CAR-NK programs for solid and hematologic cancers, while it has no approved products for commercial sale.
Develops AlloNK (AB-101), an off-the-shelf, cryopreserved allogeneic NK-cell therapy candidate for B-cell-driven autoimmune diseases. The company has prioritized refractory rheumatoid arthritis as its lead indication, while AlloNK is being evaluated in ongoing trials across autoimmune diseases. Its pipeline also retains CAR-NK candidates for solid and hematologic cancers.
Originated as a GC Cell spinout, with an exclusive, royalty-bearing license to specified NK-cell intellectual property and technology in the world excluding Asia, Australia, and New Zealand. With no products approved for commercial sale, the business depends on clinical development, regulatory progress, manufacturing, and commercialization of its candidates within that licensed territory.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| May 11, 2026 | Wedbush | Reiterate | Rating: —Target: $18 | Target: $40 |
| May 8, 2026 | H.C. Wainwright | Target | Target: — | Target: $35 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $349.4M · Total debt $9.8M · Total assets $368.6M · Shareholders' equity $347.5M
- Revenue
- $0
- Operating income
- −$26.9M
- Net income
- −$25.0M
No dividends on record.
| Institutions | 82.61% | 40.39M shares | |
|---|---|---|---|
| 74 holders · as of Jun 30, 2026 | |||
| Insiders | 3.15% | 1.54M shares | |
| 8 holders · as of Sep 11, 2026 | |||
| Strategic holders | 8.98% | 4.39M shares | |
| 1 holder · as of May 28, 2026 | |||
| Other | 5.26% | 2.57M shares | |
| remainder | |||
48.89M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Ra Capital Management, L.P.Institution | 36.73% | 17.96M | as of Jun 30, 2026 |
GC Corp.1Strategic10 percent owner | 8.98% | 4.39M | filed May 28, 2026 |
Viking Global Investors LPInstitution | 5.33% | 2.60M | as of Jun 30, 2026 |
Blackstone Inc.Institution | 4.92% | 2.40M | as of Jun 30, 2026 |
5Am Venture Management, LLCInstitution | 4.81% | 2.35M | as of Jun 30, 2026 |
- GC Corp. reports a block also reported by another filer; it is counted once, under that filer.
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Sep 8, 2026 | Fred Aslan | director, officer: Chief Executive Officer | −23,429 | $10.92 |
| Sep 3, 2026 | Subhashis Banerjee | officer: Chief Medical Officer | −1,100 | $11.16 |
| Sep 3, 2026 | Jennifer Bush | officer: COO, CLO, Compliance Officer | −8,391 | $11.16 |
| Sep 3, 2026 | Christopher Horan | officer: Chief Tech Operations Officer | −10,366 | $11.16 |
| Sep 3, 2026 | Fred Aslan | director, officer: Chief Executive Officer | −61,888 | $11.16 |
- Nkarta
Allogeneic CD19 CAR-NK therapy for B-cell-driven autoimmune disease
- Adicet Bio
Off-the-shelf gamma delta T-cell therapy across autoimmune diseases
- Allogene Therapeutics
Allogeneic CD19/CD70 CAR-T program for rheumatology indications
- Kyverna Therapeutics
Autologous CD19 CAR-T program for B-cell-driven autoimmune disease
- Cabaletta Bio
Autologous CD19 CAR-T program across multiple autoimmune diseases
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Artiva Biotherapeutics | $8.16 | +4.21% | $382.8M | — | — | — | — |
| Nkarta | $2.91 | +0.87% | $206.1M | — | — | — | — |
| Adicet Bio | $9.27 | +3.80% | $83.5M | — | — | — | — |
| Allogene Therapeutics | $1.71 | +1.18% | $583.3M | — | — | 125.7 | — |
| Kyverna Therapeutics | $7.53 | +5.76% | $432.9M | — | — | — | — |
| Cabaletta Bio | $2.52 | +2.24% | $401.1M | — | — | — | — |
| Median | — | — | 125.7 | — |